Investors braced for a bumpy ride ahead of Ceradyne's
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Ceradyne with four of six analysts rating it hold. While analysts still rate the stock a hold, they are a little more optimistic about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $131.9 million in revenue this quarter. That would represent a rise of 31% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.62 per share. Estimates range from $0.48 to $0.72.
What our community says:
CAPS All-Stars are solidly backing the stock, with 98.6% giving it an "outperform" rating. The greater community concurs with the All-Stars, as 97.1% give it a rating of "outperform." Fools are bullish on Ceradyne and haven't been shy with their opinions lately, logging 460 posts in the past 30 days. Ceradyne has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Ceradyne's profit has risen year-over-year by an average of more than threefold over the past five quarters. Revenue has now gone up for three straight quarters. The company raised its gross margin by 10.6 percentage points in the last quarter. Revenue rose 61.3% while cost of sales rose 38.3% to $94.2 million from a year earlier.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Ceradyne now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.